Robert Deignan leads ATS to the First AppEsteem Certification

Robert Deignan is the co-founder and the Chief Executive Officer of Inbound Call Experts. ICE is a company that provides solutions to software application clients. Robert Deignan is an experienced e-commerce executive. He is a graduate of Purdue University where he studied a Bachelor of a Science in Business Management. He went to St. Thomas Aquinas for his basic education. He has served in various capacities in different companies including working as the Executive Vice President of iS3 Inc in Boyton Florida. He is also the co-founder of Frankline Inc.

About ATS Digital Services

Inbound Call Experts (ICE) changed its name to ATS Digital Services. It was the first ever call Services Company to be certified by AppEsteem. The certification requires the fulfillment of 39 parameters of compliance. The company offers support services for software applications. ICE is a brainchild of veteran cybersecurity experts and software gurus who had worked for Microsoft Corporation. ATS has been providing support services to clients via a remote access screen-sharing application and via telephone engagement. The company states on its website that they focus on complete compliance to the customers’ needs. When he was interviewed regarding the certifications, Robert Deignan said that after reviewing their work operations, they realized that they met most of AppEsteem’s requirements and therefore they decided to make the request for certification. The certification has sent a positive signal to security companies, software vendors and service regulators that ATS offers state-of-the-art service that has caught the eye of the industry kingpins. The certification also confirms that ATS is a consumer-friendly service organization.

The Certification from AppEsteem

The certification from AppEsteem includes input from regulators in government, security organizations, the software industry, call centers and consumer groups. In addition, AppEsteem also has its own requirements which must be fulfilled before a certification is granted. The conditions laid out by AppEsteem are meant to protect the consumer against malpractices. AppEsteem also seeks to ensure that there is a more reliable software downloading industry. On its part, AppEsteem expressed optimism that their certification will offer vulnerable consumers a haven when it comes to online software services. The AppEsteem President, Mr. Dennis Batchelder pointed out that AppEsteem hopes to weed out fraudulent call centers.

https://www.inthebite.com/2016/01/79th-silver-sailfish-derby-starts-tomorrow/

Sahm Adrangi Shorts Proteostasis

If Sahm Adrangi is right, which he tends to be when it comes to predicting failing companies, investors should avoid Proteostasis Therapeutics, Inc. when it comes to traditional investing. Proteostasis is still in its developmental stages and its main medication is for the treatment of cystic fibrosis. Unfortunately, although Proteostasis is touting it as a breakthrough medication for the debilitating disease, Sahm Adrangi believes the drug is ineffective. The medication known as PTI-428 will most likely fail Phase 3 trials according to Sahm Adrangi and his company Kerrisdale Capital Management.

During the Phase 2 studies of the drug, the size of the placebo group was very small and the bad outcomes that came with the natural progression of the disease made the treatment group’s results look much better than they actually were. Sahm Adrangi’s research led him to believe that the company is also omitting negative results of the trial to make it look a lot more useful than it actually is.

Kerrisdale Capital Management’s research has led Sahm Adrangi to arrange a short-selling position for Proteostasis that will lead the company and their investors to make a considerable amount of money if their hypothesis is correct. Adrangi has a long history of calling out companies for pushing bad drugs onto the market in order to gain money from investors. When Proteostasis Therapeutics made the announcement of the new medication that is in development, their stock price almost doubled. This rise is expected to be temporary and will most likely fall dramatically after the results of the Phase 3 trial. While the FDA has granted PTI-428 the Orphan Drug and Breakthrough Therapy designations, Kerrisdale Capital’s experts believe these labels are misplaced.

Sahm Adrangi has predicted the ineffectiveness of several other medications that were in development stages including ones by the companies Sage Therapeutics and Bavarian Nordic. In the earlier stages of his career, he gained attention by exposing fraudulent Chinese based companies that were trading in the United States.

https://www.benzinga.com/topic/sahm-adrangi

Ara Chakerian Assisting Forest Management Thru Sustainability

The forest has been described by ancient cultures in a diversity of terms because the wood is a place that provides an abundance of types of advantages for lifestyle. Then there are persons like Ara Chakerian, who have seen within the Forest a complex of diverse terrains for physical recreation, aesthetic beauty and inspiration as well as recreational physical activities as varied as camping or archery.

 

Nature enthusiasts enjoy preserving wilderness areas and its abundant beauty and different complexity of wildlife and natural wonder, and that is one reason Ara Chackerian has been able to provide several tools that support the growing work of natural habitat preservation by Nature Conservationists and Enthusiasts. One of the tools highly used in Forest Management is forest rotation, which keeps the forests diverse while supporting wildlife in a balance with their environment.

 

It is essential to find ways and means to preserve the Forest and its complexity for the future use of the next generation and sustainability. Keen stewards like Ara Chackerian is making it possible to build a strong foundation of sustainable forest land for next-generation users. Forest professionals are always aware when professionals make a serious effort or provide significant aid to enhancing forestation, and open pathways lessen the danger to forest growth like wildfires, killing or harming endangered species, and drought.

 

Ara Chakerian

 

Three words sum the overall work of Ara Chakerian: Entrepreneur, philanthropist and angel investor. Besides carrying out his role as Managing Director of ASC Holding, LLC, Ara Chakerian spends much of his time in locating and investing healthcare institutions at the forefront of the US healthcare system, which Ara Chakerian has done for twenty years.

 

Mr. Chakerian is the CEO of BMC Diagnostics and Executive Chairman of Pipeline Rx. Lastly, Ara performs the role of Executive Vice President for PSS/World Medical, providing distribution for the international medical market. Check out Medium to know more.

 

Ara Chakerian and his wife have a diversity of philanthropic works including working with developing youth and education here in the United States, Nicaragua and Armenia.

 

 

Read more: https://patch.com/california/san-francisco/gauging-healthcare-startups-ara-chackerian-boom-or-boost

 

The Queen of Unicorn’s Success Story

Have you ever wanted your dreams to come true? The obvious truth is that many of us have. Some of us have been better at making our dreams happen than others. These types of people have truly stuck to their beliefs and have never settled for less than what they wanted. One great example of a person who has provided tireless work into achieving her dreams is Doe Deere, the creator and founder of Lime Crime. Luckily, Guest of a Guest provides an incredible interview with Doe Deere, the CEO of Lime Crime, which is tailored toward all of the dreamers out there.

 

 

Doe Deere’s story is definitely less than conventional. After all, Doe Deere is not much of a conventional person by nature. She enjoys referring to herself as the Queen of Unicorns, and her fans are lovingly known as unicorns. If you catch a glimpse of her Lime Crime makeup products online, you’ll think you’re in the center of a colorful dream. After all, it isn’t a common occurrence where bright purple lipstick is sparkled with diamond-like effects, but Doe Deere has made it possible to achieve an extraordinarily unique cosmetic experience. There is no doubt that her unicorn fans are thankful.

 

 

In Guest of a Guest’s interview with the Queen of Unicorns, one of the first questions asked is whether or not Doe Deere was always an ambitious soul. Her response is that she’s always been imaginative and ambitious, but she was able to achieve her biggest dream of moving to New York and becoming a musician at the young age of seventeen. During her time as a musician, she gained incredible marketing and collaborative skills which helped her to further develop her natural entrepreneurial ability. She spent her time in Brooklyn playing catchy music for about nine years before she moved on to the beauty industry.

 

 

You might be wondering what inspired Doe Deere to move into the world of cosmetics. In the interview, she mentions how difficult it was to find colorful and daring makeup products before 2008. She states that most of the makeup at that time was catered toward people searching for a more natural cosmetic approach. However, Doe Deere noticed that an increasingly large number of beauty-lovers wanted more vibrant colors in their makeup regimen, which is how Doe Deere began Lime Crime.

 

 

As the Queen of Unicorns, Doe Deere is frequently updating her fun assortment of bold makeup products online. Learn more:  http://www.prnewswire.com/news-releases/lime-crime-launches-mlf-velvetine-collection-for-mothers-day-300444493.html

 

 

Eric Lefkofsky Hopes to Find Better Cancer Care with Technology Company Tempus

Lung cancer is caused by a variety of both genetic and environmental risk elements. The most common environmental factor related to the condition is cigarette smoking. According to the results of a recent study, gene-smoking interactions have a significant part to play in the development of the disease. The research was conducted by a team from Dartmouth and was led by Yafang Li, PhD.

Three single-nucleotide polymorphisms (SNP’s) were discovered in the interaction investigation, and they provide probable candidate biomarkers when it comes to the diagnosis and intervention of lung cancer. Two of the detected SNP’s were for non-small cell cancer risk, while the other one represented a risk for squamous cell lung cancer. SNP’s are disparities in DNA that highlight a person’s vulnerability to developing lung cancer.

The results of the research show that the identified SNP’s can significantly improve researchers’ efficiency in classifying an individual’s chances of getting the disease through smoking. It can also help them set the best treatment plans for every individual patient. Yafang Li praised the research as the largest ever of its kind.

About Eric Lefkofsky

Eric Lefkofsky is the CEO and one of the co-founders of Tempus. Tempus is a technology company with a mission of creating the most extensive database of clinical and molecular data. Medical professionals can then use that data to establish customized treatment plans. He also helped found other companies like Lightbank and Uptake Technologies. Eric Lefkofsky graduated from the University of Michigan and got his Juris Doctor from the Law school of the same university.

Through his career, Eric Lefkofsky has contributed a lot to cancer related causes. Eric and his wife Liz frequently donate through their foundation, Lefkofsky Family Foundation. The organization was established in 2006 to push high-impact initiatives that improve people’s lives. Amongst their most recent donations include a $1 million contribution to Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.

The organization also funded the University of Michigan with $1.2 million for cancer research, and $250,000 to Weill Cornell Medicine in New York for breast cancer research. Most recently, the Lefkofsky’s joined The Giving Pledge, and have dedicated half of their lifetime wealth to charitable causes.

Besides all that giving, Lefkofsky also serves as a trustee on several boards including Chicago’s Lurie Children’s Hospital, The Museum of Science and Industry, the Art Institute of Chicago, and also World Business Chicago. He is an adjunct professor at the University of Chicago.

Facebook: https://www.facebook.com/eplefkofsky/